On Friday, Shares of Walt Disney Co (NYSE:DIS), lost - 0.33% to $107.16.
Walt Disney Company Chairman and CEO Bob Iger declared to an audience of more than 7,500 fans that Star Wars-themed lands will be coming to Disneyland park in Anaheim, Calif. , and Disney’s Hollywood Studios at Walt Disney World Resort in Orlando, Fla. , allowing Star Wars fans to step into the stories from a galaxy far, far away.
Ambitious plans to bring Star Wars to life in the two parks comprise creating Disney’s largest single themed land expansions ever at 14 acres each, transporting guests to a never-before-seen planet, a remote trading port and one of the last stops before wild space where Star Wars characters and their stories come to life.
These authentic lands will have two signature attractions. Together with the thrilling battle experience, another attraction puts guests behind the controls of one of the most recognizable ships in the galaxy, the Millennium Falcon, as they take on a customized secret mission.
The Walt Disney Company, together with its auxiliaries, operates as an entertainment company worldwide. The company operates in five segments: Media Networks, Parks and Resorts, Studio Entertainment, Consumer Products, and Interactive. The Media Networks segment operates broadcast and cable television networks, domestic television stations, and radio networks and stations; and is involved in the television production and television distribution operations.
Shares of Infinera Corp. (NASDAQ:INFN), inclined 1.09% to $24.12, during its last trading session.
Infinera, declared that its offer to acquire Transmode (OMX: TRMO) has been accepted by shareholders representing about 95.8 percent of the outstanding shares and votes in Transmode. The transaction is now slated to close on or around August 20, 2015. Of the shares tendered, about 63 percent were tendered under the cash and stock mix alternative, and about 37 percent were tendered under the all-cash alternative. This will result in final consideration comprised of about 7.9 million shares of Infinera common stock and the remainder in cash.
The combination of Infinera and Transmode brings together into one company a complementary set of customers, products, and technologies. Transmode’s strength in metro packet-optical applications complements Infinera’s industry leading long-haul and metro Cloud solutions. The combination enables Infinera to offer an end-to-end portfolio addressing the metro aggregation market counting metro core, metro edge, and metro access with solutions optimized for fast growing applications counting mobile fronthaul and backhaul, broadband aggregation, and business Ethernet services with Metro Ethernet Forum (MEF) certification.
“The combination of Infinera and Transmode makes sense from both a market and cultural perspective and I am excited to see how the teams will build off of each other’s strengths,” said Andrew Schmitt, research director, Carrier Transport Networking at IHS Research. “This acquisition positions Infinera to capitalize on the growing metro market as it starts a transition to 100G.”
Infinera Corporation provides optical transport networking equipment, software, and services for telecommunications service providers, Internet content providers, cable operators, wholesale and enterprise carriers, research and education institutions, and government entities worldwide.
Finally, Synthetic Biologics Inc (NYSEMKT:SYN), ended its last trade with -2.47% loss, and closed at $2.37.
Synthetic Biologics, stated financial results for the three and six months ended June 30, 2015, and offered an operational update.
“We continue to successfully execute against our planned milestones and are encouraged by the progress of our two lead microbiome drug candidates,” said Jeffrey Riley, Chief Executive Officer. “We initiated Phase 2a clinical trials for SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). We also initiated a Phase 2 clinical trial for SYN-010 to evaluate the efficacy in reducing the production of methane in the gut which is perceived as the underlying cause of pain, bloating and constipation associated with irritable bowel syndrome and constipation (IBS-C).”
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
